SEC Tracker
Get the app

Medline MDLN

Medline reports Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Third quarter net sales of $7.9 billion, up 10.4%
  2. Third quarter net income of $318 million, down 1.2%
  3. Nine months net sales of $22.9 billion, up 10.9%
  4. Raising full year 2026 Organic Sales guidance to 10.0% to 10.5%

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Medline files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a press release with financial details.
  2. Third quarter net sales were $7.9 billion, up 10.4% year-over-year.
  3. Net income was $318 million, down 1.2%.
  4. Adjusted EBITDA was $1.0 billion, up 11.8%.
  5. For the nine months, net sales were $22.9 billion, up 10.9%.
  6. Net income was $696 million, down 28.8%.
  7. Adjusted EBITDA was $2.8 billion, up 5.0%.
  8. Medline raised full-year 2026 organic sales guidance to 10.0% to 10.5% from 9.0% to 10.0%.
  9. It reaffirmed Adjusted EBITDA guidance of $3.3 billion to $3.4 billion.
  10. The board authorized a $1 billion share repurchase program.

10 of 10 claims matched the filing text.

From the filing

Item 2.02. Results of Operations and Financial Condition.

Item 2.02. Results of Operations and Financial Condition.

On November 4, 2026, Medline Inc. issued a press release announcing results for the third quarter and the first nine months ended September 26, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto.1

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or in the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is furnished with this Current Report on Form 8-K.

Exhibit No.

Description of Exhibit

99.1

Medline Inc. Press Release d ated November 4, 2026

104

The Cover Page of the Medline Inc.'s Current Report on Form 8-K dated November 4, 2026, formatted in Inline XBRL.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 4, 2026

MEDLINE INC.

By:

/s/ Jessi L. Corcoran

Name: Jessi L. Corcoran

Title: Chief Accounting Officer

November 4, 2026

Medline Reports Third Quarter and Nine Months 2026 Results

• Third quarter net sales of $7.9 billion, an increase of 10.4%2

• Third quarter net income of $318 million, a decrease of 1.2%3

• Third quarter Adjusted EBITDA 1 of $1.0 billion, an increase of 11.8%4

• Nine months net sales of $22.9 billion, an increase of 10.9%5

• Nine months net income of $696 million, a decrease of 28.8%6

• Nine months Adjusted EBITDA 1 of $2.8 billion, an increase of 5.0%7 • Raising full year 2026 Organic Sales 2 guidance to 10.0% to 10.5% from 9.0% to 10.0%8 and reaffirming Adjusted EBITDA 2 guidance of $3.3 billion to $3.4 billion9

• Board of Directors authorized a $1 billion share repurchase program10

NORTHFIELD, Ill., Nov. 4, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline" or the "Company") (Nasdaq: MDLN), the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all points of care 3 , today reported its operating results for the three and nine months ended September 26, 2026.

"Medline delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business," said Jim Boyle, chief executive officer of Medline. "Our commercial execution remains strong, including continued progress toward our annual total new custo

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Solventum SOLV public float $13.1B, Jun 30, 2025
  2. Hologic HOLX public float $13.6B, Mar 29, 2025, over 18 months old
  3. Align Technology ALGN public float $11.1B, Jun 30, 2025
  4. West Pharmaceutical Services WST public float $15.7B, Jun 30, 2025
  5. Baxter International BAX public float $16.0B, Jun 30, 2025